Viatris to Acquire Pacira BioSciences for $1.65B, Expanding…

Event summary

Viatris Inc. agrees to acquire Pacira BioSciences for $1.65 billion in cash, at $36.50 per share.
Pacira brings two patent-protected, high-margin products: EXPAREL® for postsurgical pain and ZILRETTA® for osteoarthritis knee pain.
Pacira generated $746 million in revenue and $177 million in adjusted EBITDA in the last twelve months ended June 30, 2026.
The transaction is expected to close by the end of 2026 and be immediately accretive to Viatris' financial guidance metrics.
Viatris plans to leverage its global infrastructure to expand the reach of Pacira's products.

The big picture

Viatris' acquisition of Pacira BioSciences positions it as a leader in non-opioid pain management therapies, an area with significant unmet need. The deal aligns with Viatris' strategy to build its innovative medicines business and complements its fast-acting meloxicam opportunity. The transaction is consistent with Viatris' disciplined approach to capital allocation, preserving financial flexibility while aiming to create value through cost and revenue synergies.

What we're watching

Integration Challenges: How Viatris will integrate Pacira's commercial, market access, and R&D capabilities into its existing infrastructure.
Market Expansion: The pace at which Viatris can expand the reach of EXPAREL and ZILRETTA across selected international markets.
Financial Impact: Whether the acquisition will sustain Viatris' path to revenue and earnings growth as anticipated.